NasdaqGS:UTHRBiotechs
Did Completing the TETON-1 IPF Trial Just Shift United Therapeutics' (UTHR) Investment Narrative?
United Therapeutics recently completed its Phase 3 TETON-1 trial of inhaled treprostinil in idiopathic pulmonary fibrosis, a double-blind, placebo-controlled 52-week study assessing whether the drug can slow lung function decline.
This milestone, building on earlier TETON-2 findings, could be pivotal for expanding the Tyvaso franchise into IPF and informing potential regulatory filings.
Next, we’ll examine how completing the TETON-1 Phase 3 IPF trial could reshape United Therapeutics’...